Skip to main content
Top
Published in: Clinical & Experimental Metastasis 5/2015

01-06-2015 | Research Paper

Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases

Authors: Lydia G. M. van der Geest, Jorine’t Lam-Boer, Miriam Koopman, Cees Verhoef, Marloes A. G. Elferink, Johannes H. W. de Wilt

Published in: Clinical & Experimental Metastasis | Issue 5/2015

Login to get access

Abstract

The aim of this study was to determine trends in incidence, treatment and survival of colorectal cancer (CRC) patients with synchronous metastases (Stage IV) in the Netherlands. This nationwide population-based study included 160,278 patients diagnosed with CRC between 1996 and 2011. We evaluated changes in stage distribution, location of synchronous metastases and treatment in four consecutive periods, using Chi square tests for trend. Median survival in months was determined, using Kaplan–Meier analysis. The proportion of Stage IV CRC patients (n = 33,421) increased from 19 % (1996–1999) to 23 % (2008–2011, p < 0.001). This was predominantly due to a major increase in the incidence of lung metastases (1.7–5.0 % of all CRC patients). During the study period, the primary tumor was resected less often in Stage IV patients (65–46 %) and the use of systemic treatment has increased (29–60 %). Also an increase in metastasectomy was found in patients with one metastatic site, especially in patients with liver-only disease (5–18 %, p < 0.001). Median survival of all Stage IV CRC patients increased from 7 to 12 months. Especially in patients with metastases confined to the liver or lungs this improvement in survival was apparent (9–16 and 12–24 months respectively, both p < 0.001). In the last two decades, more lung metastases were detected and an increasing proportion of Stage IV CRC patients was treated with systemic therapy and/or metastasectomy. Survival of patients has significantly improved. However, the prognosis of Stage IV patients becomes increasingly diverse.
Literature
1.
go back to reference Netherlands Cancer R. Dutch Cancer Figures. 2013 Netherlands Cancer R. Dutch Cancer Figures. 2013
2.
go back to reference van der Pool AE, Damhuis RA, Ijzermans JN et al (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 14:56–61PubMedCrossRef van der Pool AE, Damhuis RA, Ijzermans JN et al (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 14:56–61PubMedCrossRef
3.
go back to reference Elferink MA, van Steenbergen LN, Krijnen P et al (2010) Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989–2006. Eur J Cancer 46:1421–1429 (Oxford, England : 1990)PubMedCrossRef Elferink MA, van Steenbergen LN, Krijnen P et al (2010) Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989–2006. Eur J Cancer 46:1421–1429 (Oxford, England : 1990)PubMedCrossRef
4.
go back to reference van Steenbergen LN, Elferink MA, Krijnen P et al (2010) Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989–2006. Ann Oncol 21:2206–2212PubMedCrossRef van Steenbergen LN, Elferink MA, Krijnen P et al (2010) Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989–2006. Ann Oncol 21:2206–2212PubMedCrossRef
5.
go back to reference Kanas GP, Taylor A, Primrose JN et al (2012) Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4:283–301PubMedCentralPubMed Kanas GP, Taylor A, Primrose JN et al (2012) Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4:283–301PubMedCentralPubMed
6.
go back to reference Hackl C, Gerken M, Loss M et al (2011) A population-based analysis on the rate and surgical management of colorectal liver metastases in southern Germany. Int J Colorectal Dis 26:1475–1481PubMedCrossRef Hackl C, Gerken M, Loss M et al (2011) A population-based analysis on the rate and surgical management of colorectal liver metastases in southern Germany. Int J Colorectal Dis 26:1475–1481PubMedCrossRef
7.
go back to reference Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683PubMedCentralPubMedCrossRef Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683PubMedCentralPubMedCrossRef
8.
go back to reference Gonzalez M, Poncet A, Combescure C et al (2013) Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 20:572–579PubMedCrossRef Gonzalez M, Poncet A, Combescure C et al (2013) Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 20:572–579PubMedCrossRef
9.
go back to reference de Cuba EM, Kwakman R, Knol DL et al (2013) Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev 39:321–327PubMedCrossRef de Cuba EM, Kwakman R, Knol DL et al (2013) Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev 39:321–327PubMedCrossRef
10.
go back to reference de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed
11.
go back to reference Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedCrossRef Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedCrossRef
12.
go back to reference Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135–142PubMedCrossRef Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135–142PubMedCrossRef
13.
go back to reference Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef
14.
go back to reference Cirocchi R, Trastulli S, Abraha I et al (2012) Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. The Cochrane database of systematic reviews 8:CD008997 Cirocchi R, Trastulli S, Abraha I et al (2012) Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. The Cochrane database of systematic reviews 8:CD008997
15.
go back to reference Verhoef C, de Wilt JH, Burger JW et al (2011) Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer 47(Suppl 3):S61–S66 (Oxford, England : 1990)PubMedCrossRef Verhoef C, de Wilt JH, Burger JW et al (2011) Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer 47(Suppl 3):S61–S66 (Oxford, England : 1990)PubMedCrossRef
16.
go back to reference Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology (ICD-O). World Health Organization, Geneva Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology (ICD-O). World Health Organization, Geneva
17.
go back to reference Wittekind C, Greene FL, Hutter RVP et al (2004) TNM atlas. Springer, Berlin Wittekind C, Greene FL, Hutter RVP et al (2004) TNM atlas. Springer, Berlin
18.
go back to reference Nagtegaal ID, Tot T, Jayne DG et al (2011) Lymph nodes, tumor deposits, and TNM: are we getting better? J Clin Oncol 29:2487–2492PubMedCrossRef Nagtegaal ID, Tot T, Jayne DG et al (2011) Lymph nodes, tumor deposits, and TNM: are we getting better? J Clin Oncol 29:2487–2492PubMedCrossRef
19.
go back to reference Parnaby CN, Bailey W, Balasingam A et al (2012) Pulmonary staging in colorectal cancer: a review. Colorectal Dis 14:660–670PubMedCrossRef Parnaby CN, Bailey W, Balasingam A et al (2012) Pulmonary staging in colorectal cancer: a review. Colorectal Dis 14:660–670PubMedCrossRef
20.
go back to reference Bipat S, Niekel MC, Comans EF et al (2012) Imaging modalities for the staging of patients with colorectal cancer. Neth J Med 70:26–34PubMed Bipat S, Niekel MC, Comans EF et al (2012) Imaging modalities for the staging of patients with colorectal cancer. Neth J Med 70:26–34PubMed
21.
go back to reference Mitry E, Guiu B, Cosconea S et al (2010) Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59:1383–1388PubMedCrossRef Mitry E, Guiu B, Cosconea S et al (2010) Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59:1383–1388PubMedCrossRef
22.
go back to reference Wiering B, Vogel WV, Ruers TJ et al (2008) Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig Surg 25:413–420PubMedCrossRef Wiering B, Vogel WV, Ruers TJ et al (2008) Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig Surg 25:413–420PubMedCrossRef
23.
go back to reference Mitry E, Rollot F, Jooste V et al (2013) Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer 49:2919–2925 (Oxford, England : 1990)PubMedCrossRef Mitry E, Rollot F, Jooste V et al (2013) Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer 49:2919–2925 (Oxford, England : 1990)PubMedCrossRef
24.
go back to reference Damjanov N, Weiss J, Haller DG (2009) Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease. Oncologist 14:963–969PubMedCrossRef Damjanov N, Weiss J, Haller DG (2009) Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease. Oncologist 14:963–969PubMedCrossRef
25.
go back to reference Benoist S, Pautrat K, Mitry E et al (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92:1155–1160PubMedCrossRef Benoist S, Pautrat K, Mitry E et al (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92:1155–1160PubMedCrossRef
26.
go back to reference Hu CY, Bailey CE, You YN et al (2015) Time trend analysis of primary tumor resection for stage iv colorectal cancer: less surgery, improved survival. JAMA Surg 150:245–251PubMedCrossRef Hu CY, Bailey CE, You YN et al (2015) Time trend analysis of primary tumor resection for stage iv colorectal cancer: less surgery, improved survival. JAMA Surg 150:245–251PubMedCrossRef
27.
go back to reference Scheer MG, Sloots CE, van der Wilt GJ et al (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19:1829–1835PubMedCrossRef Scheer MG, Sloots CE, van der Wilt GJ et al (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19:1829–1835PubMedCrossRef
28.
go back to reference Vargas GM, Sheffield KM, Parmar AD et al (2014) Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg 18:369–377PubMedCentralPubMedCrossRef Vargas GM, Sheffield KM, Parmar AD et al (2014) Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg 18:369–377PubMedCentralPubMedCrossRef
29.
go back to reference Jones RP, Vauthey JN, Adam R et al (2012) Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 99:1263–1269PubMedCrossRef Jones RP, Vauthey JN, Adam R et al (2012) Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 99:1263–1269PubMedCrossRef
30.
go back to reference Hattori N, Kanemitsu Y, Komori K et al (2013) Outcomes after hepatic and pulmonary metastasectomies compared with pulmonary metastasectomy alone in patients with colorectal cancer metastasis to liver and lungs. World J Surg 37:1315–1321PubMedCrossRef Hattori N, Kanemitsu Y, Komori K et al (2013) Outcomes after hepatic and pulmonary metastasectomies compared with pulmonary metastasectomy alone in patients with colorectal cancer metastasis to liver and lungs. World J Surg 37:1315–1321PubMedCrossRef
31.
go back to reference Chua TC, Saxena A, Liauw W et al (2012) Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases–a systematic review. Eur J Cancer 48:1757–1765 (Oxford, England : 1990)PubMedCrossRef Chua TC, Saxena A, Liauw W et al (2012) Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases–a systematic review. Eur J Cancer 48:1757–1765 (Oxford, England : 1990)PubMedCrossRef
32.
go back to reference Sorbye H, Cvancarova M, Qvortrup C et al (2013) Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 24:2354–2360PubMedCrossRef Sorbye H, Cvancarova M, Qvortrup C et al (2013) Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 24:2354–2360PubMedCrossRef
33.
go back to reference Kornmann M, Staib L, Wiegel T et al (2013) Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer. Clin Colorectal Cancer 12:54–61PubMedCrossRef Kornmann M, Staib L, Wiegel T et al (2013) Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer. Clin Colorectal Cancer 12:54–61PubMedCrossRef
34.
go back to reference Khattak MA, Martin HL, Beeke C et al (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254PubMedCrossRef Khattak MA, Martin HL, Beeke C et al (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254PubMedCrossRef
35.
go back to reference Lemmens VE, Klaver YL, Verwaal VJ et al (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128:2717–2725PubMedCrossRef Lemmens VE, Klaver YL, Verwaal VJ et al (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128:2717–2725PubMedCrossRef
36.
go back to reference Mol L, Koopman M, van Gils CW et al (2013) Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol 52:950–955PubMedCrossRef Mol L, Koopman M, van Gils CW et al (2013) Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol 52:950–955PubMedCrossRef
37.
go back to reference Downs-Canner S, Bahar R, Reddy SK et al (2012) Indeterminate pulmonary nodules represent lung metastases in a significant portion of patients undergoing liver resection for malignancy. J Gastrointest Surg 16:2256–2259PubMedCrossRef Downs-Canner S, Bahar R, Reddy SK et al (2012) Indeterminate pulmonary nodules represent lung metastases in a significant portion of patients undergoing liver resection for malignancy. J Gastrointest Surg 16:2256–2259PubMedCrossRef
Metadata
Title
Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases
Authors
Lydia G. M. van der Geest
Jorine’t Lam-Boer
Miriam Koopman
Cees Verhoef
Marloes A. G. Elferink
Johannes H. W. de Wilt
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2015
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-015-9719-0

Other articles of this Issue 5/2015

Clinical & Experimental Metastasis 5/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine